Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Cash & Equivalents (2016 - 2025)

Cardiff Oncology's Cash & Equivalents history spans 15 years, with the latest figure at $17.5 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 66.06% year-over-year to $17.5 million; the TTM value through Dec 2025 reached $17.5 million, down 66.06%, while the annual FY2025 figure was $17.5 million, 66.06% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $17.5 million at Cardiff Oncology, up from $10.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $79.9 million in Q1 2025 and bottomed at $10.1 million in Q3 2025.
  • The 5-year median for Cash & Equivalents is $16.9 million (2022), against an average of $21.2 million.
  • The largest annual shift saw Cash & Equivalents plummeted 90.88% in 2021 before it skyrocketed 328.23% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $11.9 million in 2021, then soared by 36.88% to $16.3 million in 2022, then surged by 32.47% to $21.7 million in 2023, then surged by 137.68% to $51.5 million in 2024, then tumbled by 66.06% to $17.5 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Cash & Equivalents are $17.5 million (Q4 2025), $10.1 million (Q3 2025), and $10.8 million (Q2 2025).